Browsing Tag
AUCATZYL
1 post
Syncona’s £1.04bn NAV faces 2026 clinical test as £250m capital-return strategy takes shape
Syncona is targeting at least ÂŁ250 million of shareholder returns as four 2026 biotech catalysts test whether its ÂŁ1.04 billion NAV can finally translate into realised cash.